PA8482001A1 - Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson adhd y microadenomas - Google Patents

Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson adhd y microadenomas

Info

Publication number
PA8482001A1
PA8482001A1 PA19998482001A PA8482001A PA8482001A1 PA 8482001 A1 PA8482001 A1 PA 8482001A1 PA 19998482001 A PA19998482001 A PA 19998482001A PA 8482001 A PA8482001 A PA 8482001A PA 8482001 A1 PA8482001 A1 PA 8482001A1
Authority
PA
Panama
Prior art keywords
microadenomas
treatment
parkinson
pharmaceutical agents
adhd disease
Prior art date
Application number
PA19998482001A
Other languages
English (en)
Inventor
Elisa Rose Jackson
Mclean Stafford
Stevin Howard Zorn
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8482001A1 publication Critical patent/PA8482001A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE AL USO DE CIERTOS DERIVADOS DE PIRIDO [1,2-A]-PIRAZINA, TAMBIÉN DESCRITOS COMO COMPUESTOS DE BIS-AZABICÍCLICOS Y DEFINIDOS POR LA FÓRMULA (I) DE ESTE DOCUMENTO, EN EL TRATAMIENTO DE LA ENFERMEDAD DE PARKINSON, EL TRASTORNO DE HIPERACTIVIDAD CON DÉFICIT DE ATENCIÓN Y MICROADENOMAS EN MAMÍFEROS, Y A COMPOSICIONES RELACIONADAS
PA19998482001A 1998-09-21 1999-09-15 Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson adhd y microadenomas PA8482001A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10119198P 1998-09-21 1998-09-21
US10386898P 1998-10-12 1998-10-12

Publications (1)

Publication Number Publication Date
PA8482001A1 true PA8482001A1 (es) 2000-05-24

Family

ID=26798000

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998482001A PA8482001A1 (es) 1998-09-21 1999-09-15 Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson adhd y microadenomas

Country Status (38)

Country Link
US (2) US6300329B1 (es)
EP (1) EP1115402A1 (es)
JP (1) JP2002526448A (es)
KR (3) KR100468340B1 (es)
CN (1) CN1319013A (es)
AP (1) AP1456A (es)
AR (1) AR029739A1 (es)
AU (1) AU760230B2 (es)
BG (1) BG105445A (es)
BR (1) BR9913975A (es)
CA (1) CA2344670A1 (es)
CO (1) CO5140075A1 (es)
CZ (1) CZ20011006A3 (es)
DZ (1) DZ2894A1 (es)
EA (2) EA200100204A1 (es)
EE (1) EE200100179A (es)
GE (1) GEP20033081B (es)
GT (1) GT199900154A (es)
HN (1) HN1999000146A (es)
HR (1) HRP20010209A2 (es)
HU (1) HUP0103691A3 (es)
ID (1) ID28028A (es)
IL (2) IL164839A0 (es)
IS (1) IS5852A (es)
MA (1) MA26690A1 (es)
MY (1) MY127939A (es)
NO (1) NO20011409L (es)
NZ (1) NZ509855A (es)
OA (1) OA11653A (es)
PA (1) PA8482001A1 (es)
PE (1) PE20001084A1 (es)
PL (1) PL346904A1 (es)
SK (1) SK3592001A3 (es)
TN (1) TNSN99177A1 (es)
TR (2) TR200101357T2 (es)
TW (1) TW518225B (es)
WO (1) WO2000016777A1 (es)
YU (1) YU21701A (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
GB0027020D0 (en) 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AU2002315336A1 (en) * 2001-06-18 2003-01-02 Psychiatric Genomics, Inc. Method for neural stem cell differentiation using 5ht-1a agonists
US20030036555A1 (en) * 2001-08-03 2003-02-20 Boehringer Ingelheim Pharma Kg Pramipexole for the treatment of ADHD
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
EP1765075A4 (en) * 2004-06-10 2010-11-10 Mclean Hospital Corp PYRIMIDINES, IN PARTICULAR URIDINE, USED IN TREATMENTS ON PATIENTS WITH BIPOLAR DISORDERS
EP1784199A4 (en) * 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
TW200800306A (en) 2005-09-12 2008-01-01 Wyeth Corp Sustained-release formulation and uses thereof
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
US9066903B2 (en) * 2006-02-28 2015-06-30 The United States Of America As Represented By The Department Of Veterans Affairs Pharmacological treatment of Parkinson's disease
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008083442A1 (en) * 2007-01-10 2008-07-17 Brc Operations Pty Limited Method for formulating combination medications for adhd
CN101318020B (zh) * 2007-06-06 2011-09-28 四川科瑞德制药有限公司 抗焦虑或/和抗抑郁的药物组合物及用途
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
CN104892589A (zh) 2014-03-07 2015-09-09 中国科学院上海药物研究所 一类杂环化合物、其制备方法和用途
US11426366B2 (en) 2015-05-15 2022-08-30 Arizona Board Of Regents On Behalf Of The Universsity Of Arizona Compositions and methods for treating motor disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990008148A1 (en) * 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
WO1992000075A1 (en) * 1990-06-29 1992-01-09 Pfizer Inc. Pyridopyrazine derivatives for treating substance abuse and addiction
US5281607B1 (en) * 1992-10-08 1998-05-19 Univ New York Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases
GB9408084D0 (en) * 1994-04-23 1994-06-15 Boots Co Plc Medical treatment
CA2192975C (en) * 1994-06-14 1999-09-21 Anton F. Fliri Benzimidazolone derivatives
US5877183A (en) * 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
HN1999000146A (es) * 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.

Also Published As

Publication number Publication date
HUP0103691A2 (hu) 2002-02-28
ID28028A (id) 2001-05-03
BR9913975A (pt) 2001-06-19
TR200101357T2 (tr) 2001-08-21
AU760230B2 (en) 2003-05-08
KR100468340B1 (ko) 2005-01-27
US6608064B2 (en) 2003-08-19
KR20010075222A (ko) 2001-08-09
TW518225B (en) 2003-01-21
KR20030088512A (ko) 2003-11-19
HUP0103691A3 (en) 2003-01-28
HN1999000146A (es) 2000-11-11
AP2001002102A0 (en) 2001-03-31
NZ509855A (en) 2003-04-29
HRP20010209A2 (en) 2002-04-30
IL141507A0 (en) 2002-03-10
EP1115402A1 (en) 2001-07-18
CO5140075A1 (es) 2002-03-22
US6300329B1 (en) 2001-10-09
US20010034347A1 (en) 2001-10-25
NO20011409L (no) 2001-03-28
PE20001084A1 (es) 2000-10-18
GEP20033081B (en) 2003-10-27
KR20040054752A (ko) 2004-06-25
PL346904A1 (en) 2002-03-11
CN1319013A (zh) 2001-10-24
GT199900154A (es) 2001-03-06
AR029739A1 (es) 2003-07-16
IS5852A (is) 2001-02-20
CA2344670A1 (en) 2000-03-30
WO2000016777A1 (en) 2000-03-30
YU21701A (sh) 2004-07-15
BG105445A (en) 2001-12-29
DZ2894A1 (fr) 2003-12-15
NO20011409D0 (no) 2001-03-20
MA26690A1 (fr) 2004-12-20
TR200402083T2 (tr) 2004-10-21
EA200301063A1 (ru) 2004-12-30
AU5383199A (en) 2000-04-10
OA11653A (en) 2004-12-08
EE200100179A (et) 2002-10-15
AP1456A (en) 2005-09-30
CZ20011006A3 (cs) 2001-09-12
JP2002526448A (ja) 2002-08-20
SK3592001A3 (en) 2001-12-03
TNSN99177A1 (fr) 2005-11-10
IL164839A0 (en) 2005-12-18
EA200100204A1 (ru) 2001-08-27
MY127939A (en) 2007-01-31

Similar Documents

Publication Publication Date Title
PA8482001A1 (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson adhd y microadenomas
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
UY26086A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos
BR0213877A (pt) Compostos orgânicos
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
BRPI0413022A (pt) derivados de 3-amino cromado e 2-amino tetralina
ES2194314T3 (es) Derivados de benzopirano sustituidos para el tratamiento de inflamaciones.
PA8432901A1 (es) Compuestos de piridilpirrol
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0116323A (pt) Compostos de heterociclilindazol e -azaindazol como ligandos de 5-hidroxitriptamina-6
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
BRPI0411528A (pt) uso de isomalte como prebiótico
AR029383A1 (es) Moleculas pequenas, los intermediarios para su sintesis, las composiciones farmaceuticas que las contienen y su uso para preparar un medicamento destinado al tratamiento o la profilaxis de enfermedades inflamatorias o mediadas por celulas inmunes
MA27734A1 (fr) DERIVES HEXAHYDROPYRAZINO [1,2-a]PYRIMIDINE-4,7-DIONE SUBSTITUES SUR L'AZOTE, METHODE POUR LEUR PRODUCTION ET LEUR UTILISATION EN TANT QUE MEDICAMENTS
BR0010716A (pt) Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas
BRPI0616264B8 (pt) composto 7-[2-[4-(6-flúor-3-metil-1,2-benzissoxazol-5- il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c]-pirimidin-5-amina, e, composição farmacêutica
BR9713261A (pt) Tricìclicos substituìdos
BR0016133A (pt) Composto, formulação farmacêutica, e, uso de um composto
UY28377A1 (es) Agentes terapeuticos
BR0212966A (pt) Fosfonita, uso da mesma, complexo de metal de transição, processo para a preparação e uso do mesmo, e, processos para a adição de ácido cianìdrico a uma ligação dupla olefìnica na presença de um catalisador, e para a isomerização de nitrilas orgânicas na presença de um catalisador
AR018162A1 (es) Pirroles substituidos, composicion farmaceutica y el uso de los mismos para la preparacion de dicha composicion farmaceutica
ECSP034776A (es) Indolinonas sustituidas en posicion 6, su preparacion y su utilizacion como medicamentos
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
BRPI0409570A (pt) derivados de 3-benzidrilideno-8-aza-biciclo[3.2.1]octano com atividade receptora de opióides
BR9912817A (pt) Composição terapêutica à base de isoflavonóides destinada a ser utilizada no tratamento dos tumores por agentes citotóxicos